SGR-1505-101 Study

What is the SGR-1505-101 study?

The SGR-105-101 study is researching SGR-1505, an investigational study drug, to determine if SGR-1505 can help people with B-cell blood cancers. The purpose of this study is to answer the following questions:

What we learn in this study has the potential to improve options for people with B-cell lymphoma (blood cancer).

Who can join the SGR-1505-101 study?

Study participants may be able to join the study if they meet the following requirements:

Other study requirements will apply

See if you may qualify

What will happen during the study?

This is what you can expect during the SGR-1505-101 study.

Informed consent:

A member of the study team will review the Informed Consent Form (ICF) with you, which explains the study in more detail. You must sign the ICF before receiving any Screening assessments.

Screening tests and procedures:

You will attend a screening visit to see if you are eligible for the SGR-1505-101 study.

Study treatment period

You will take the study medication (SGR-1505) once daily or every 12 hours for each cycle period, depending on what type of B-cell lymphoma you have. The Sponsor will inform the study doctor which dosing schedule you will belong to.

  • Cycle 1 has 5 study clinic visits
  • Cycle 2 has 4 study clinic visits
  • Each Cycle from Cycle 3 onwards has only 1 study clinic visit

For every day that includes a study clinic visit, you will take your study drug dose at the clinic.

Follow-up:

Study follow-ups will occur within 28 days of the last dose of the study medication. These follow-ups can be conducted over the phone.

Study survival follow-ups will occur every 3 months from end of treatment until death, lost to follow-up status, or end of study, whichever occurs first.

Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.